SPOTLIGHT: Callisto restructures Atiprimod deal

Callisto Pharmaceuticals has restructured its license agreement with Genzyme for Atiprimod, Callisto's lead drug to treat advanced carcinoid cancer. The new agreement eliminates all milestone payments and reduces royalties owed to Genzyme. In return for the reduced future payments to Genzyme, Callisto is paying an upfront fee in 2008. "This restructured licensing agreement significantly improves the potential economic upside value for Atiprimod and puts us in a stronger position to further develop and commercialize the product," said Gabriele M. Cerrone, chairman of Callisto. "We recently completed enrollment in our Atiprimod Phase II trial in advanced carcinoid cancer patients and we expect to complete an interim analysis of the data by the end of the first quarter of this year. We believe this new agreement with Genzyme will provide substantial help in obtaining financing for a potential Phase III trial." Release

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.